Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.

Nat Commun · 2026 · PMC13237085 · PMID 41951609

Europe PMC DOI

hedged sentence

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

did not reach statistical significancep = 0.075so close (0.05 < p ≤ 0.1)

While there was no difference in SLiM-CRAB PFS, biochemical PFS was significantly longer in patients who achieved VGPR or better (NR vs 52.2 months; two-sided log-rank, p = 0.014) and duration of response was also longer, although this comparison did not reach statistical significance (two-sided log-rank, p = 0.075) (Fig. 3A–C ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.